Sitagliptin Dosage

Medically reviewed by Drugs.com. Last updated on Dec 5, 2023.

Applies to the following strengths: 50 mg; 25 mg; 100 mg; (as base) 25 mg; (as base) 50 mg; (as base) 100 mg

Usual Adult Dose for:

Diabetes Type 2

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Adult Dose for Diabetes Type 2

100 mg orally once a day

Comments:

When used in combination with an insulin secretagogue (e.g. sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.

Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Renal Dose Adjustments

Mild renal impairment (eGFR 45 mL/min/1.73 m2 or greater): No adjustment recommended
Moderate renal impairment (eGFR 30 mL/min/1.73 m2 to less than 45 mL/min/1.73 m2): 50 mg orally once a day
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): 25 mg orally once a day

Liver Dose Adjustments

Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Use caution; no data available

Precautions

CONTRAINDICATIONS:

Hypersensitivity to this drug or any of the product excipients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: 25 mg orally once a day
Peritoneal dialysis: 25 mg orally once a day

May be administered without regard to timing of dialysis

Other Comments

Administration advice:

May take with or without food
Missed doses should be taken as soon as the patient remembers. More than one dose should not be taken on the same day.

General:

In clinical trials, sitagliptin has not been shown to improve glycemic control in pediatric patients 10 to 17 years old with type 2 diabetes; this drug is not approved for use in pediatric patients.
This drug should not be used in patients with type 1 diabetes.
Has not been studied in patients with a history of pancreatitis; it is unknown whether these patients may be at an increased risk for the development of pancreatitis.

Monitoring:

Assess renal function prior to initiating therapy and periodically thereafter
Monitor for signs and symptoms of heart failure
Blood glucose and hemoglobin A1C measurements should be measured periodically to assess efficacy
Observe for signs and symptoms of pancreatitis

Patient Advice:

Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
Instruct patient to report signs and symptoms of pancreatitis; if persistent, severe abdominal pain occurs, seek medical advice promptly.
Serious allergic reactions may occur; if symptoms occur, seek medical advice promptly.
Hypoglycemia may occur, more commonly when used in combination with insulin or a sulfonylurea.
Patients should understand the importance of adhering to dietary instructions and regular physical activity; during periods of stress such as fever, trauma, infection, or surgery, management of diabetes may change and patients should be advised to seek medical advice.
Instruct patients to contact their health care provider if they develop severe and persistent joint pain.
Instruct patients to contact their health care provider if they develop signs or symptoms of heart failure.